Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at San Diego, California
Dates
study started
estimated completion
Principal Investigator
by Mario Chojkier, M.D.
Photo of Mario Chojkier
Mario Chojkier

Description

Summary

Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.

Official Title

Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver

Keywords

Obesity Insulin Resistance Fenretinide

Eligibility

You can join if…

Open to people ages 18-65

  • BMI >30

You CAN'T join if...

  • Diabetes Requiring Medication
  • Poorly Controlled Co-Morbidities

Location

  • University of California at San Diego Hospitals
    San Diego California 92161 United States

Lead Scientist at UCSD

Details

Status
currently not accepting new patients, but might later
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT00546455
Phase
Phase 2
Study Type
Interventional
Last Updated